However, AKI occurred within 9 weeks with the use of the CTLA-4 inhibitor tremelimumab or the combination of the CTLA-4 inhibitor ipilimumab and the PD-1 inhibitor nivolumab. The gene discussed is CTLA4; the disease is acute kidney injury.